PARP inhibitor Archives -

Filing beckons as Lynparza hits the mark in adjuvant breast cancer

https://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/

Triple Negative Breast Cancer Drug Development Digital Summit

https://pharmaphorum.com/events/triple-negative-breast-cancer-drug-development-digital-summit/

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

https://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/

AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancer

https://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/

NICE backs Lynparza across the board for BRCA+ovarian cancer

https://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

Strong results for AZ’s Lynparza will help in PARP battle

https://pharmaphorum.com/news/lynparza-parp-battle/

Search